ESR1 and endometrial cancer: The limitations of this study include the following: (1) the retrospective nature of the analysis, despite the data being collected prospectively, may lead to incomplete data collection and potential non-uniformity between the two groups; (2) the results should currently be interpreted with caution due to the limited number of patients and follow-up; (3) the absence of recurrence cases in low-risk tumors due to the generally good prognosis of the disease; and (4) the absence of a validated ER positivity cutoff in endometrial cancer.